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Abstract
Background. The development of brain metastases (BM) is one of the most feared complications of cancer due to
the substantial neurocognitive morbidity and a grim prognosis. In the past decade, targeted therapies and checkpoint inhibitors have demonstrated promising intracranial response rates for tumors of multiple histologies. As
overall survival for these patients improves, there is a growing need to identify issues surrounding patient survivorship and to standardize physician practice patterns for these patients. To date, there has not been an adequate
study to specifically explore these questions of survivorship and practice standardization for patients with advanced cancer and BM.
Methods. Here, we present results from a cross-sectional survey in which we analyze responses from 237 patients,
209 caregivers, and 239 physicians to identify areas of improvement in the clinical care of BM.
Results. In comparing physician and patient/caregiver responses, we found a disparity in the perceived discussion
of topics pertaining to important aspects of BM clinical care. We identified variability in practice patterns for this
patient population between private practice and academic physicians. Many physicians continue to have patients
with BM excluded from clinical trials. Finally, we obtained patient/physician recommendations on high-yield areas
for federal funding to improve patient quality of life.
Conclusion. By identifying potential areas of unmet need, we anticipate this wealth of actionable information will
translate into tangible benefits for both patients and caregivers. Future studies are needed to validate our findings.
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communication, standardize treatment recommendations
in a rapidly evolving field, and facilitate the development
of new therapeutics.

Methods
Participants

Study Measures
The study was conceptualized, developed, and sponsored by the American Brain Tumor Association (ABTA),
a nonprofit organization dedicated to brain tumor patient
services and research. Surveys were administered by
Penn, Schoen, and Berland (PSB) to PSB survey panels.
Commercial panel providers, such as PSB, continuously
solicit cancer patients, caregivers, and physicians from a
diverse background, and are frequently used by pharmaceutical companies due to their broad reach in recruiting
participants. Additionally, surveys were also provided
to patients, caregivers, and physicians on lists provided
by partner organizations (Kidney Cancer Association,
LUNGevity Foundation, Melanoma Research Foundation,
and Society for Neuro-Oncology). Eligible participants
were contacted via email with a link to an online questionnaire. There were no reminder emails sent, and there
was no additional re-contact with survey responders’ postsurvey completion.
A predetermined goal of approximately 200 survey
responders for each survey population (ie, patient, caregiver, and physician) was targeted. As stated above, we
employed a recruiting strategy using lists provided by
partner organizations and commercial survey panels
to maximize the diversity of our cohort. However, this
strategy results in a non-probabilistic sample, as not
everyone in the total population of metastatic brain
tumor patients and caregivers would theoretically be
able to take the survey as potential respondents voluntarily joined survey or partner organization panels. For
non-probabilistic samples such as these, a margin of
error equivalent is often used. However, this calculation
is dependent on knowing the approximate size of the
metastatic brain tumor population, which to our knowledge, does not exist in current literature. Therefore, a
conservative estimate of total population of adults as the
base was used. This yielded a sampling margin of error
equivalent of ±6.9% at the 95% confidence level.
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The subjects of the survey were patients, caregivers, and
physicians. All patients carried a diagnosis of BM, with
histologically confirmed disease from any metastatic solid
tumor. A caregiver was defined as an adult individual (eg,
family members, nursing staff), who was not a clinician, that
provided support (eg, medical, financial, emotional, physical)
to a patient with a confirmed diagnosis of BM. Physicians
provided direct clinical care to patients carrying a diagnosis
of BM and included neuro-oncologists, medical oncologists,
neurosurgeons, and radiation oncologists. Patient, caregiver,
and physician survey answers were not matched on the patient or physician level. All participants were required to be
able to read and respond to questions in English.

Neuro-Oncology
Practice

Brain metastases (BM) are the most common central
nervous system (CNS) malignancy and portend a grim
prognosis. Current estimates suggest that approximately
50 000-150 000 patients are diagnosed annually in the
United States alone, and historically, median survival has
been on the order of a few months after diagnosis.1–5 As
progression of intracranial disease is the cause of death
in up to 50% of patients with BM,2 treatments for BM are
an emerging unmet need in modern oncology. To this end,
recent clinical trials evaluating checkpoint inhibitors6,7
and targeted therapies8–12 have demonstrated promising
intracranial activity. However, as prognoses for these patients improve, there has been increased awareness of issues surrounding patient survivorship and the variability
of practice4 across oncologists for this challenging patient
population. These questions have major ramifications
for adequately treating patient symptoms and improving
quality of life (QoL).
Historically, clinical outcomes, such as overall survival,
progression-free survival, and treatment-related toxicity,
have been used to evaluate therapeutic efficacy in oncology. These metrics, however, do not capture the holistic effect of treatment on a patient’s everyday life. For
example, patient symptoms and psychosocial stressors
are difficult to quantify and may be under-recognized in
clinical practice, resulting in greater morbidity and decreased QoL for the patient.13–16 In recent years, patientrelated outcomes (PROs), defined as a report of the status
of a patient’s health that comes directly from the patient
without interpretation by a health care professional,17 have
emerged as a popular tool to longitudinally track facets
of a patient’s well-being. Consequently, PROs are being
incorporated in standard clinical workflows and have accelerated a paradigm shift in oncology towards patientcentered care.18–20
To date, relatively few PRO studies have been performed
for brain tumor patients. Brain tumors, compared to systemic cancers, present unique challenges due to long-term
neurocognitive sequelae.21 From the patients’ perspective, brain tumors are catastrophic events, as they usually
present after an unexpected event (eg, seizure, hemiparesis)
and are accompanied by persistent limitations in neurologic function due to subsequent supportive and tumordirected therapies.22–24 Further compounding this issue is
the difficulty from the physician perspective in integrating
recent advances in a rapidly evolving field without a clear
standard of care. This conundrum may result in variability
in physician practices and messages relayed to patients/
caregivers that can evoke stress and confusion. Current
PRO studies in neuro-oncology have predominantly surveyed glioma patients, and have revealed important insights about an inadequate understanding of the disease
process from patients,25,26 and unmet financial and psychosocial needs for caregivers.21,27–30 However, to our knowledge, there has not been a dedicated study evaluating
these endpoints or physician practice patterns, specific
to the BM population. Hence, using a cross-sectional
survey of patients, caregivers, and physicians, we sought
to collect information on unmet patient/caregiver needs,
physician practice regimens for BM, and patient-caregiverphysician recommendations on ways to improve patient
care and increase federal resources for BM. We anticipate
this information will improve patient-caregiver-clinician
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Statistical Analyses
Descriptive statistics were used to summarize survey results from each survey population, and within the physician category by workplace type (eg, private, academic,
and other). For patients, 3 summary tables were generated,
stratifying patients by sex, age at diagnosis of BM, and histology of primary cancer. Chi-square tests were used to
test for differences in sex, age, and primary cancer type,
using P < .05 as a significance threshold. For caregivers, 3
summary tables were generated, stratifying caregivers by
sex, age at patients’ diagnosis of BM, and histology of primary cancer for the patient of whom he/she took care of.
Chi-square tests were used to test for differences in sex,
age, and histology of primary cancer for the patient, using
P < .05 as a significance threshold. For physicians, 4 summary tables were generated, stratifying physicians by sex,
age, number of cancer patients managed per month, and
workplace type (private, academic, and other). Chi-square
tests were used to test for differences by workplace type,
using P < .05 as a significance threshold. Questions that
overlapped between groups were also analyzed to assess differences between respective respondent groups
using chi-square tests. All analyses of this study were approved by the Piedmont Health and Case Western Reserve
University Institutional Review Boards and performed
using R (v3.6.2) and its libraries.

Results
Participants
We identified 45 133 patients, 1582 caregivers, and 2019
physicians, and contacted them via email. From August 13
to September 16, 2018, 1841 patients agreed to participate
in the survey and 237 of these patients were identified as
eligible for our study based on the screening questions.
A total of 209 caregivers completed our survey. From
June 16 to 25, 2019, 239 physicians completed our survey.
Additional survey responders after these time frames were
not included in our analysis, given financial constraints
and our pre-specified goal of approximately 200 survey responders for each population. 200 survey responses from
each cohort were obtained through PSB panels. The remainder of responses was obtained through social media
postings by the ABTA or partner organizations.
The majority of patients and caregivers were Caucasian,
young or middle-aged adults (Table 1), and had at least
a college education (Supplementary Table 1). The most
common symptom that patients endorsed were headaches,

dizziness, and balance issues (Figure 1). Caregivers provided physical, emotional, and financial support to patients, which frequently had emotional (87.6%) and mental
(70.8%) impacts on caregiver well-being (Supplementary
Table 2). A significant portion of caregivers reported feeling
sad (48.8%), depressed (32.5%), and overwhelmed (40.7%).
Social, psychiatric, and physical coping means were used
by caregivers to assist with these emotional burdens.
Surveyed physicians were predominantly male (80%) and
Caucasian (58%; Table 1), and worked in a private practice
setting (Table 2). Most (78.2%) were medical oncologists
with 10+ years of experience.

Participant-Caregiver-Physician Concerns About
Clinical Care of Brain Metastases
In our survey, we found discrepancies in the perceived discussion of the risk and implications of developing BM, from
the patient/caregiver and physician perspective (Table 3).
While patient and caregiver responses were not linked,
the provided responses were largely similar. These discussions generally first occurred after the initial diagnosis of
a metastatic solid tumor. Given the stress associated with
this diagnosis, it can be difficult for the physician, within
the constraints of a clinic visit, to present all necessary information to the patient, and even more challenging for
the patient/caregiver to process a great deal of potentially
life-altering information. Many topics, such as a general
overview of BM, worrisome symptoms, treatment options,
and patient advocacy resources, were felt to have been
discussed more frequently from the perspective of physicians than from that of patients or caregivers. Consistent
with this, a higher percentage of patients/caregivers, compared to physicians, indicated a desire for increased discussion on these issues. All parties felt that more detailed
discussion regarding the prognostic and therapeutic implications of BM was desired in the visits following a diagnosis of metastatic cancer. The most common discussion
points that patients/caregivers wanted more information
on included: survival rates of BM, treatment options, and
patient advocacy support. 91.5% of patients felt that the
information provided by the physician about treatments
targeting the BM were either “very helpful” or “somewhat
helpful” (Supplementary Table 3).
Given the substantial neurologic morbidity and grim
prognosis, a diagnosis of a BM can be a life-altering event
for patients that can evoke many questions and concerns.
In our survey, the most common questions that were asked
by patients/caregivers to the physician after a diagnosis of
BM included: worrisome symptoms, treatment options/
success, and impact on QoL (Supplementary Table 4).
After the diagnosis of a BM, physicians commonly referred
patients to patient support groups, published research,
and online educational resources for more information
(Supplementary Table 5). About 80%-90% of patients felt
that the information provided by the physician for social
or financial support was helpful (Supplementary Table 3).
Next, we queried physicians on their greatest concerns for
patients with a diagnosis of BM (Supplementary Table 6). The
most common concerns included: neurologic symptoms,
treatment options/success, and impact of BM on patient
QoL. Significantly more private practice-affiliated physicians,
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Patient-caregiver-physician surveys contained questions
about demographics, BM symptoms, discussion of BM diagnosis by the clinician, psychosocial concerns from the
patient, available treatment options for BM, advocacy resources specific to patients with BM, BM-specific clinical
trials, and the level of familiarity and expectation of the
ABTA and other brain tumor patient advocacy organizations. Physicians were also asked about their level of experience in treating general oncology patients, and whether
they worked in an academic or private setting.

  

239

N (Sample size)

48 (20.1)

Female

88 (36.8)
69 (28.9)
45 (18.8)
9 (3.8)

35-44

45-54

55-64

65+

54 (22.6)
81 (33.9)
42 (17.6)

Midwest

South

West

10 (4.2)
69 (28.9)
6 (2.5)
4 (1.7)

Black/African American/Caribbean-American

Asian

American Indian or Alaska Native

Native Hawaiian or Pacific Islander

—
—
—
—
—
—
—

3-6 mo ago

7 mo to <12 mo ago

1-3 yr ago

4-5 yr ago

6-10 yr ago

11 or more years ago

Don’t know

  

by a chi-square test.
first current primary cancer type of patients under the care of caregivers.

1 (0.4)

1 (0.4)

7 (3.0)

13 (5.6)

65 (27.8)

59 (25.2)

61 (26.1)

27 (11.5)

2 (0.9)

1 (0.4)

11 (4.7)

23 (9.8)

194 (82.9)

47 (20.1)

90 (38.5)

40 (17.1)

57 (24.4)

10 (4.2)

25 (10.7)

37 (15.8)

78 (33.3)

84 (35.9)

129 (55.1)

105 (44.9)

234

Patients

1 (0.5)

14 (6.7)

13 (6.2)

36 (17.2)

77 (36.8)

41 (19.6)

21 (10.0)

6 (2.9)

1 (0.5)

3 (1.4)

7 (3.3)

23 (11.0)

174 (83.3)

43 (20.6)

71 (34.0)

53 (25.4)

42 (20.1)

10 (4.7)

32 (15.3)

30 (14.4)

67 (32.1)

70 (33.4)

113 (54.1)

96 (45.9)

209

Caregivers

<.001

.434

.169

<.001

.017

<.001

.331

<.001

<.001

P Value for Differences by Groupa
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bThe

aGenerated

—

0-3 mo ago

The time when the patient was first diagnosed with metastatic brain tumors (%)

139 (58.2)

White/Caucasian

Race (%)—multiple

62 (25.9)

Northeast

Region (%)

28 (11.7)

Under 35

Age at time of survey (%)

191 (79.9)

Male

Sex (%)

Physicians

Characteristics Summary

Physician, Patient, and Caregiver Characteristics

Neuro-Oncology
Practice

Table 1.
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108

N (Sample size)

0 (0.0)

35 (32.4)
24 (22.2)
7 (6.5)

45-54

55-64

19 (27.9)

2 (1.9)
4 (3.7)

Pediatric oncologist

Radiation oncologist

56 (51.9)
56 (51.9)
53 (49.1)
51 (47.2)
49 (45.4)
56 (51.9)
27 (25.0)
58 (53.7)

Thoracic

GI

GU

Gyn

Sarcoma

Lymphoma

Pediatrics

Melanoma
31 (28.7)

63 (58.3)

Breast

9 (13.2)

25 (36.8)

10 (14.7)

25 (36.8)

18 (26.5)

13 (19.1)

19 (27.9)

23 (33.8)

21 (30.9)

32 (47.1)

22 (32.4)

6 (8.8)

2 (2.9)

7 (10.3)

8 (12.7)

28 (44.4)

12 (19.0)

34 (54.0)

22 (34.9)

17 (27.0)

25 (39.7)

28 (44.4)

34 (54.0)

31 (49.2)

27 (42.9)

9 (14.3)

5 (7.9)

1 (1.6)

44 (69.8)

7 (11.1)

0 (0.0)

2 (3.2)

7 (11.1)

54 (85.7)

15 (23.8)

48 (76.2)

2 (3.2)

12 (19.0)

11 (17.5)

26 (41.3)

12 (19.0)

63

Other

.01

.084

.244

.083

.037

<.001

.021

.064

.009

.279

.071

.045

.12

.052

.001

<.001

.103

.001

.088

.021

P Value for Differences by Workplaceb

.028

.042

.149

.072

.019

<.001

.009

.029

.01

.192

.032

.274

>.999

.15

.002

<.001

.321

<.001

.06

.035

P Value for Differences Between Private and Academicb

Downloaded from https://academic.oup.com/nop/article/8/6/662/6319895 by library@baptisthealth.net user on 30 November 2021

 I do not have any expertise/
sub-specialization

54 (50.0)

Head/neck

Your expertise/sub-specialization in one or
more disease sites (%)—multiple

4 (3.7)

47 (69.1)

7 (6.5)
96 (88.9)

3 (4.4)

1 (1.5)

0 (0.0)
1 (0.9)

11 (16.2)

56 (82.4)

18 (26.5)

50 (73.5)

23 (33.8)

1 (0.9)

Neurosurgeon

   Medical oncologist or hematologist

Neuro oncologist

Neurologist

Your field(s) (%)—multiple

Resident

Fellow

Practicing physician

107 (99.1)

15 (13.9)

Female

Your role (%)

93 (86.1)

Male

Sex of physicians (%)

65+

9 (13.2)

36 (33.3)

35-44

26 (38.2)

6 (5.6)

10 (14.7)

68

Academic

25-34

Age of physicians at the time of survey (%)

Privatea

Summary of Physician Characteristics by Workplace

Physician Characteristics

Table 2.
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108

N (Sample size)

8 (7.4)
21 (19.4)
36 (33.3)
9 (8.3)

4-5 yr

6-10 yr

11-15 yr

16-20 yr

35 (32.4)

151-200

201+

42 (38.9)
22 (20.4)

South

West

0 (0.0)

Other

  

1 (1.5)

0 (0.0)

0 (0.0)

1 (1.6)

0 (0.0)

62 (98.4)

13 (20.6)

16 (25.4)

16 (25.4)

18 (28.6)

10 (15.9)

13 (20.6)

8 (12.7)

15 (23.8)

8 (12.7)

6 (9.5)

3 (4.8)

12 (19.0)

8 (12.7)

10 (15.9)

16 (25.4)

5 (7.9)

7 (11.1)

5 (7.9)

63

Other

.043

.013

.05

.002

P Value for Differences by Workplaceb

.039

.003

.043

<.001

P Value for Differences Between Private and Academicb

workplace was coded as academic, private (which included “private practice as a solo partner,” “private practice with multiple practitioners,” and “private clinical research”) and other.

0 (0.0)

Administration

3 (4.4)

64 (94.1)

7 (10.3)

23 (33.8)

11 (16.2)

27 (39.7)

10 (14.7)

11 (16.2)

10 (14.7)

9 (13.2)

13 (19.1)

13 (19.1)

2 (2.9)

11 (16.2)

8 (11.8)

12 (17.6)

14 (20.6)

6 (8.8)

13 (19.1)

4 (5.9)

68

Academic
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aPhysician

0 (0.0)

Research

Clinical work

108 (100.0)

27 (25.0)

Midwest

The majority of your time spent (%)

17 (15.7)

Northeast

Region of physicians (%)

15 (13.9)
23 (21.3)

101-150

11 (10.2)
14 (13.0)

81-100

9 (8.3)

20-50

51-80

1 (0.9)

<20

The number of cancer patients you personally manage within your practice each month
(%)

31 (28.7)

3 (2.8)

1-3 yr

21 yr or more

0 (0.0)

<1 yr

How long you have worked in oncology
since the end of your training (%)

Privatea

Physician Characteristics

Continued

Neuro-Oncology
Practice

Table 2.
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Table 3. Topics of Discussion Between Patient/Caregiver and Physician Regarding the Risk of Developing Brain Metastases, and Topic of
Information on Brain Metastases Each Group Wished They Would Like to See More of
Topic of Discussion Between Patient/Caregiver and Physician

105 (44.9)

111 (53.1)

<.001

112 (47.9)

123 (58.9)

<.001

139 (58.2)

107 (45.7)

78 (37.3)

<.001

66 (27.6)

99 (42.3)

78 (37.3)

.003

Overview of brain metastases

161 (67.4)

Symptoms to be aware of

191 (79.9)

Plan/schedule for testing

Survival rates

101 (42.3)

102 (43.6)

85 (40.7)

.825

Caregiver support

67 (28.0)

91 (38.9)

67 (32.1)

.04

Treatment options

157 (65.7)

118 (50.4)

107 (51.2)

.001

Physicians

Patients

Caregivers

Topic of Information You Would Like to Know More About

P Value for Differences by Groupa

Overview of brain metastases

60 (25.1)

97 (41.5)

92 (44.0)

<.001

Symptoms to be aware of

61 (25.5)

102 (43.6)

93 (44.5)

<.001

Plan/schedule for testing

57 (23.8)

87 (37.2)

56 (26.8)

.004

Where to go for information/support

68 (28.5)

101 (43.2)

94 (45.0)

<.001

Survival rates

92 (38.5)

122 (52.1)

98 (46.9)

.01

Caregiver support

80 (33.5)

87 (37.2)

89 (42.6)

.138

Treatment options

105 (43.9)

109 (46.6)

96 (45.9)

.834

values are generated by a chi-square test.
  

  

Table 4.

Treatment Options Recommended by Physicians Following BM Diagnosis, Stratified by Group and Physician Workplace

Recommended Treatment Option (%)
Surgery

Physiciansa

Patients

Caregivers

P Value for Differences by Groupb

53 (22.2)

60 (25.6)

35 (16.7)

.075

Stereotactic radiation

126 (52.7)

56 (23.9)

35 (16.7)

<.001

Whole brain radiation

123 (51.5)

63 (26.9)

63 (30.1)

<.001

Chemotherapy

125 (52.3)

78 (33.3)

96 (45.9)

<.001

Homeopathic treatment

12 (5.0)

20 (8.5)

12 (5.7)

.261

Participation in a clinical trial

55 (23.0)

42 (17.9)

23 (11.0)

.004

Observation

18 (7.5)

33 (14.1)

33 (15.8)

.017

Recommended Treatment Option (Physicians
only) (%)

Private

c

Academic

Other

P Value for Differences Between
Private and Academicb

Surgery

30 (27.8)

10 (14.7)

12 (19.0)

.067

Stereotactic radiation

56 (51.9)

38 (55.9)

33 (52.4)

.714

Whole brain radiation

66 (61.1)

27 (39.7)

30 (47.6)

.009

Chemotherapy

56 (51.9)

33 (48.5)

36 (57.1)

.784

Homeopathic treatment

9 (8.3)

2 (2.9)

1 (1.6)

.263

Participation in a clinical trial

24 (22.2)

17 (25.0)

13 (20.6)

.809

Observation

10 (9.3)

4 (5.9)

4 (6.3)

.603

aThe counts of treatment options recommended by the physician to his/her patient(s) are calculated based on the average of the recommended
options across combinations of primary cancer types and brain metastases types.
bP values are generated by a chi-square test.
cPhysician workplace was coded as academic, private (which included “private practice as a solo partner,” “private practice with multiple practitioners,” and “private clinical research”) and other.

  

compared to academic physicians, were concerned about
their patients’ neurologic symptoms (50.0% vs 30.9%;
P = .019). Academic physicians were more likely to be worried about the current state of published research for BM and
patient eligibility for clinical trials.

Treatment Options
Patients in our cohort received care from oncology/neurooncology (43.2/38.5%), radiation oncology (32.5%), neurosurgery (28.6%), and palliative care (17.5%; Supplementary
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Most common symptoms endorsed by patients diagnosed with brain metastases.

Table 3). Physicians, patients, and caregivers indicated
that the most popular recommended treatment options, following the diagnosis of a BM, were stereotactic
radiosurgery (SRS), whole-brain radiation therapy (WBRT),
and chemotherapy (Table 4). Participation in a clinical trial
was among the least recommended options (23.0% of
physicians and 17.9% of patients). Private practice physicians, compared to academic physicians, were significantly more likely to recommend WBRT (61.1 vs 39.7%,
P = .009). About 88.5% of patients reported satisfaction
with the choice of BM-targeted treatment (Supplementary
Table 3).
Physicians stated that patient QoL, intracranial and extracranial disease burden, the presence of neurologic symptoms, and the number of viable systemic options were the
most important factors in deciding on BM-directed treatments (Supplementary Table 7). Academic physicians were
more likely to consider clinical research and treatment
toxicity in their decision-making process (Supplementary
Table 8). The most preferred resources for physicians in the
treatment of BM patients were National Comprehensive
Cancer Network (NCCN) and American Society of Clinical
Oncology (ASCO) published guidelines.
Finally, more than half of all surveyed physicians indicated that more clinical trials for BM patients were needed
(Supplementary Figure 1). A large barrier to effective treatments for BM is the relative paucity of clinical trials specifically for patients diagnosed with BM, due to perceived
poor prognosis. The majority of physicians (59.1% private,
71.9% academic) stated that one or more patients in their
care were denied participation in clinical trials, specifically due to the presence of BM (Supplementary Table 9).
The most desired trial designs were those evaluating novel

systemic therapies, followed by those using novel radiation approaches to avoid WBRT (Supplementary Table 10).

Federal Government Advocacy
Very few survey responders (7.5% of physicians, 11.0%
of patients) felt that the federal government was doing
enough for patients with advanced cancer and BM (Figure
2). The consensus among physicians, patients, and caregivers was that the highest yield area for federal assistance
is increased treatment/research funding for BM, followed
by quicker FDA approvals of BM treatments. Other desired
areas of improvement included more clinical trial availability and patient advocacy resources. When physician responses were stratified based on workplace, academic
physicians were more likely to advocate for increased
treatment/research funding and clinical trial availability
for patients with BM (Supplementary Figures 1 and 2).
Increased federal government funding for BM treatments
and research remained the most popular area of advocacy
among all physicians.

Discussion
Our findings represent one of the first patient/caregivercentered studies designed specifically to evaluate the
complex and unique needs of patients diagnosed with
BM. We then integrated these insights with input from
clinicians on practice patterns and high-yield areas of improvement. A central finding of our study was a disparity in
the perceived discussion of topics pertaining to BM, from
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Figure 2. High-yield areas of federal intervention for patients with brain metastases.
  

physicians and patients/caregivers. These topics included
especially important issues, such as prognosis and treatment intent. Our findings are consistent with existing data;
for example, more than half of patients with advanced
cancer have an overly optimistic perception of their prognosis.31,32 Furthermore, our data suggest that a significant
portion of patients diagnosed with BM may be making
treatment decisions without fully understanding treatment
ramifications and expected outcomes.
Patients, caregivers, and physicians reported QoL as
a paramount concern and the most influential factor
dictating selection of treatment. Therefore, interventions

directed at improving prognostic awareness, with a focus
on QoL, are needed. More effective patient-clinician communication and additional patient-centric resources would
enable patients to make more informed decisions about
their treatment and likely have downstream benefits in
psychological well-being. In our study, only 17.5% of patients saw a palliative care physician during their treatment course. As palliative or best supportive care is an
emerging treatment option in consensus guidelines,33 we
recommend consideration of palliative care referrals for
this patient population. QoL efforts should also be directed
towards caregiver well-being, as a significant number of
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medical oncologists. There may be important concerns from
other physician specialists that were not captured. Similarly,
our study did not gauge the experience of patients and caregivers on the impact of interdisciplinary care coordination.
Another limitation is the fact that patient-caregiverphysician survey responses were not matched, thereby
interpretation of results cannot be extrapolated to reflect experiences of patient/caregiver, patient/physician,
or caregiver/physician pairs. While the patient and caregiver responses were not linked, the provided responses
within these cohorts were largely similar, which gives
some credence to the collected data on general symptoms
and unmet needs for the BM population. Additionally, the
majority of patients, caregivers, and physicians that were
contacted did not respond to our survey, which may be a
source of participation bias. While the response rate for
caregivers (13%) and physicians (10%) are in line with
historical norms for surveys in which there is no reward,
other than altruism, for participating,44 we note the low
response rate from the patient cohort (4%) and acknowledge that our population may be skewed towards patients
of high functional status. Many patients carrying a diagnosis of BM also have concomitant extracranial disease,
which may inhibit survey engagement due to limitations
in functional status. Finally, our study did not differentiate between patients with different histologies and treatments received (eg, steroids, immunotherapy), as we tried
to capture broadly applicable aspects of BM clinical care
as a first step. To address these issues, we will plan future
longitudinal studies by surveying the patient population of
a specific physician at different time points. These efforts
would capture patients of poor functional status, assess
the needs of patients with asymptomatic BM, link patient/
caregiver/physician responses, and measure the impact of
various interventions (eg, steroids, memantine after WBRT,
anticonvulsants) during the patient’s treatment course.
In summary, we performed a large cross-sectional
survey in which we compared responses from physicians, caregivers, and patients to identify areas of improvement in the clinical care of BM. Our study is one of
the first studies tailored specifically for these patients, a
unique population due to their neurocognitive sequelae
and limited prognosis. We collected actionable information on patient/caregiver psychosocial needs, variability
in physician practice patterns, and recommendations
on high-yield areas for federal funding to improve the
clinical care of BM. Our conclusions are tempered by the
low response rate from patients and the lack of patient/
caregiver/physician-matched data and will require prospective validation in future studies. Nonetheless, our
hope is that these findings are a first step towards planning larger studies that identify survivorship issues for a
specific subset within the BM population (eg, histologyspecific, neurologically asymptomatic patients), evaluate the longitudinal impact of specific interventions
on patient QoL, and obtain input from other physician
specialists. Results from these studies may inspire future
quality improvement measures to improve specific facets of the care of patients with BM. These efforts will be
instrumental towards improving outcomes for a dismal
disease.
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caregivers endorsed deleterious psychosocial effects from
caregiver burden. Caregivers who suffer emotional distress stemming from their loved one’s illness have worse
physical and psychological health, which may translate
into worse outcomes for the patient.34–37
Another novel aspect of our study is our assessment of
physician practice patterns and recommendations for the
field of BM. Due to the recent emergence of CNS-penetrant
targeted therapies8,10–12,38–40 and immune checkpoint inhibitors6,7 for BM, some oncologists now consider up-front
systemic therapy in asymptomatic BM’s in order to delay
surgery or radiation until BM progression and to minimize
surgical morbidity41 or radiation-induced neurotoxicity.
Given rapidly evolving treatment paradigms for BM, we
hypothesized that there would be variability in treatment
recommendations across physicians. In our survey, private
practice physicians, compared to academic physicians,
were significantly more likely to recommend WBRT as a
treatment for BM. Additionally, private practice physicians
were more likely to be concerned about treating neurologic symptoms. As physicians stated that their most preferred educational resources for management of BM were
NCCN and ASCO guidelines, we recommend continued
correspondence to our oncology colleagues using these
resources. Furthermore, our study adds to the growing
body of evidence illustrating the paucity in clinical trials
specific for the BM population. As patients continue to be
denied participation in a clinical trial due to the presence of
BM, we urge our colleagues to prioritize planning of trials
evaluating intracranial efficacy of novel systemic therapies
or radiation approaches, with flexible inclusion criteria for
patients with BM.
Finally, very few survey responders felt the federal
government is currently doing enough for patients diagnosed with BM. The area of highest need was unanimous
among patients, caregivers, and physicians: more research funding for BM treatments. Therefore, we recommend increased federal resources to better understand BM
pathophysiology and design more effective treatments.
Additionally, we note that supportive care of patients/caregivers is a frequently overlooked and unmet need, which
can result in deleterious effects on QoL and emotional
well-being.34–37 Funding for patient advocacy efforts, focusing on psychological well-being through one-on-one
counseling and social/emotional resources,42 is needed.
Our study has several important limitations. First, given
the lack of an established reporting system that facilitates
quantitation of the metastatic brain tumor population, we
were not able to perform a statistically rigorous calculation
for sample size. The majority of our patient/caregiver cohort
were young or middle-aged adults and primarily Caucasian.
These factors may limit the generalizability of our findings.
Additionally, more than 95% of our patient/caregiver cohort endorsed symptomatic BM. Therefore, our findings
may only reflect the experiences of patients with symptomatic BM, rather than those with asymptomatic intracranial
disease. Future studies are needed to capture the needs
of patients with relatively small and asymptomatic BM,
which are increasing in incidence41 due to guidelines43 that
have resulted in increased screening for BM in cancer patients. Next, the vast majority of physician responders were
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